---
title: "Regeneron director Kathryn Guarini disposes of 400 common shares worth $340,000"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297957662.md"
description: "Regeneron director Kathryn Guarini sold 400 common shares at $850 per share on September 2, totaling $340,000. On the same day, she exercised stock options for 400 shares at $719.37 per share. Following these transactions, her direct holdings of common shares decreased to 603."
datetime: "2026-09-03T20:47:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297957662.md)
  - [en](https://longbridge.com/en/news/297957662.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297957662.md)
generator: "portal-rs"
---

# Regeneron director Kathryn Guarini disposes of 400 common shares worth $340,000

-   Regeneron director Kathryn Guarini sold 400 shares on Sep. 2 at USD 850 per share. \* She exercised stock options for 400 shares at USD 719.37 per share on the same day. \* Directly held common shares fell to 603 following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001992352-26-000007), on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)

## Related News & Research

- [Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum](https://longbridge.com/en/news/298982614.md)
- [10:07 ETREGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact SueWallSt](https://longbridge.com/en/news/297926980.md)
- [TestMu AI lance le « Cycle de vie de l'assurance » dans Kane CLI, transformant les documents d'exigences en couverture de test vérifiable](https://longbridge.com/en/news/299148825.md)
- [Neonc Technologies CEO Amir F Heshmatpour buys $135,620 of common shares](https://longbridge.com/en/news/298899583.md)
- [Agomab Therapeutics director Naimish Patel files initial beneficial ownership statement](https://longbridge.com/en/news/299091117.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**